A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin

An Open-label, Single-sequence, Drug-drug Interaction Study to Assess the Effect of BMS-963272 Coadministration on the Systemic Exposure of Rosuvastatin in Healthy Participants

Phase 1 study that assesses the effect of BMS-963272 on exposure of rosuvastatin in healthy participants

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Healthy participants, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
• Women must not be of childbearing potential (WNOCBP)
• Women and men must agree to follow instructions for methods of contraception

Exclusion Criteria:

• Any significant acute or chronic medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study.
• Any major surgery within 4 weeks of study drug administration
• Any blood transfusion or donation of blood to a blood bank or in a clinical study within 4 weeks of study drug administration
• Previous treatment with BMS-963272
• Participants who smoke, as well as, those who have stopped smoking less than 6 months prior to day 1

Other protocol-defined inclusion/exclusion criteria could apply